Tonix Pharmaceuticals Holding Corp. (TNXP)
TNXP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/0001999371-26-005730-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TNXP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001430306 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $13.1M |
| Net income | -$124.0M |
| Operating income | -$125.7M |
| Net margin | -946.2% |
| Operating margin | -959.1% |
| Revenue growth | +29.8% |
| Cash | $207.6M |
| Total assets | $277.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-09 |
| Cash and burn | $162.8M cash; operating cash flow -$41.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 19,431,516 (2026-11-06); 11,776,542 a year earlier; 23,849,341 three years earlier. 3y figure adjusted for splits (1-for-3200 overall). | Cover page 2026-11-06 |
| Reverse splits, 3 years | 2; latest 1-for-100 on 2025-02-05 | Source 2025-02-05 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the market | Latest 2025-12-29 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | EisnerAmper LLP, Iselin, New Jersey, United States; changed auditors 1 time in 24 months | 8-K 4.01 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $459K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $17.2M | -$53.3M | -$41.1M | $162.8M | No debt tags | $43.0M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $13.5M | -$40.6M | -$42.2M | $176.2M | No debt tags | $29.1M | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | $6.9M | -$40.2M | -$42.3M | $185.5M | No debt tags | $17.6M | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $5.4M | -$46.9M | -$39.6M | $207.6M | No debt tags | $13.1M | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | $3.3M | -$32.0M | -$28.8M | $190.1M | No debt tags | $10.3M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $2.0M | -$28.3M | -$14.8M | $125.3M | No debt tags | $9.8M | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | $2.4M | -$16.8M | -$16.6M | $131.7M | No debt tags | $10.0M | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | $2.6M | -$22.1M | -$14.6M | $98.8M | $8.7M | $10.1M | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2025-12-29 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-12 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy DEFINITIVE PROXY STATEMENT | DEF 14A | 2026-03-30 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -36.5% |
| 1 month | -50.9% |
| 3 months | -75.9% |
| Year to date | -80.7% |
| 1 year | -81.4% |
| From 52-week high | -84.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| XBIT | XBiotech Inc. | $1.85 | -5.37% | $56.4M |
| SPRO | Spero Therapeutics Inc. | $0.9464 | -5.35% | $55.1M |
| BOLD | Boundless Bio Inc. | $2.41 | -3.60% | $56.9M |
| VRCA | Verrica Pharmaceuticals Inc. | $3.20 | -10.11% | $55.0M |
| CING | Cingulate Inc. | $3.75 | -12.79% | $54.5M |
| INCR | Intercure Ltd. | $3.63 | -4.22% | $54.5M |
| AZR | Azora Therapeutics Inc. | $3.81 | -6.85% | $54.4M |
| XLO | Xilio Therapeutics Inc. | $7.70 | -3.08% | $54.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier